Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives two message to stakeholders, such as pharmaceutical companies, the payers, such as healthcare providers, and doctors concerning the access to and affordability of novel drugs in multiple myeloma (MM). According to Prof Harousseau, the stakeholders should find a fair price for the drugs and act transparently. The payers should focus on the patient pathway and healthcare organization. Further, doctors should not only consider the efficacy but also the efficiency. His second message to the stakeholders, payers and doctors is to work together rather than against each other.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.